FrancophonIA/ELRC3.0 huggingface dataset:
English: Pharmacotherapeutic group: Antithrombotic agents, platelet aggregation inhibitor excl. heparin.
Estonian: Farmakoterapeutiline rühm: tromboosivastased ained, trombotsüütide agregatsiooni inhibiitor, v.a hepariin, ATC-kood: B01AC
English: produced a reduction in triglycerides of 0.33 mmol/l (15%) and an increase in HDL-cholesterol of 0.10 mmol/l (10%).
Estonian: <Tsilostasooli sisaldav ravimpreparaat> 100 mg kaks korda päevas vähendas platseeboga võrreldes pärast 12-nädalast ravi triglütseriidide taset 0,33 mmol/l (15%) ja suurendas HDL-kolesterooli taset 0,10 mmol/l (10%) võrra.
English: Very common side effects (affecting more than 1 in 10 people) headache abnormal stools diarrhoea
Estonian: Väga sagedad kõrvaltoimed (esinevad rohkem kui 1 inimesel 10st)
English: Caution is advised when cilostazol is co-administered with CYP3A4 substrates with a narrow therapeutic index (e.g., cisapride, halofantrine, pimozide, ergot derivates).
Estonian: Tsilostasooli manustamisel koos CYP3A4 substraatidega, millel on teadaolevalt kitsas terapeutiline indeks (nt tsisapriid, halofantriin, pimosiid, tungaltera derivaadid), tuleb olla ettevaatlik.
English: Before you start taking <Cilostazol-containing medicinal product>, please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Estonian: Muud ravimid ja <Tsilostasooli sisaldav ravimpreparaat> Teatage oma arstile või apteekrile enne <Tsilostasooli sisaldava ravimpreparaadiga> ravi alustamist, kui te võtate või olete hiljuti võtnud või kavatsete võtta mis tahes muid ravimeid.
English: HOW TO TAKE <CILOSTAZOL-CONTAINING MEDICINAL PRODUCT>
Estonian: Kuidas <Tsilostasooli sisaldavat ravimpreparaati> võtta
English: Reduction of the dose to 50 mg twice daily is recommended in patients receiving medicines that strongly inhibit CYP3A4, for example some macrolides, azole antifungals, protease inhibitors, or medicines that strongly inhibit CYP2C19, for example omeprazole (see sections 4.4 and 4.5).
Estonian: Kui patsient kasutab ravimeid, mis CYP3A4 tugevalt inhibeerivad, näiteks teatavaid makroliide, seenevastaseid asoole, proteaasi inhibiitoreid või CYP2C19 tugevaid inhibiitoreid, näiteks omeprasooli, on soovitatav vähendada annus 50 mg-ni kaks korda päevas (vt lõigud 4.4 ja 4.5).
English: Hot flushes, hypertension, hypotension, cerebral haemorrhage, pulmonary haemorrhage, muscle haemorrhage, respiratory tract haemorrhage, subcutaneous haemorrhage
Estonian: Teadmata kuumad hood, hüpertensioon, hüpotensioon, ajuverejooks, kopsuverejooks, verejooks lihasesse, hingamisteede verejooks, nahaalune verejooks
English: Bleeding tendency, thrombocytopenia, granulocytopenia, agranulocytosis, leukopenia, pancytopenia, aplastic anaemia
Estonian: Teadmata veritsemiskalduvus, trombotsütopeenia, granulotsütopeenia, agranulotsütoos, leukopeenia, pantsütopeenia, aplastiline aneemia
English: Nausea and vomiting, dyspepsia, flatulence, abdominal pain
Estonian: Sage iiveldus ja oksendamine, düspepsia, puhitus, kõhuvalu
English: Based on AUC, the overall pharmacological activity increases by 47% when co-administered with omeprazole.
Estonian: Üldine farmakoloogiline aktiivsus suurenes AUC põhjal 47% võrra manustamisel koos omeprasooliga.
English: Rhinitis, pharyngitis
Estonian: Sage riniit, farüngiit
English: if you are taking both acetylsalicylic acid and clopidogrel, or any combination of two or more medicines which can increase your risk of bleeding [ask your doctor or pharmacist if you are not sure] if you have severe kidney disease or moderate or severe liver disease.
Estonian: − kui kasutate atsetüülsalitsüülhapet koos klopidogreeliga või samaaegselt kaht või rohkemat ravimit, mis võivad teil suurendada verejooksude riski [kui te ei ole kindel,
English: In total, 1,439 patients with intermittent claudication and no heart failure have been treated with cilostazol or placebo for up to three years.
Estonian: Tsilostasooli või platseeboga on ravitud kuni kolme aasta jooksul kokku 1439 vahelduva lonkamisega, kuid ilma südamepuudulikkuseta patsienti.
English: At lower dose levels, retardations of ossification were observed.
Estonian: Väiksemate annusete puhul täheldati luustumise hilinemist.
English: Very common Diarrhoea, abnormal faeces Common
Estonian: Väga sage kõhulahtisus, ebanormaalne väljaheide
English: Uric acid level increased, blood urea increased, blood creatinine increased
Estonian: Teadmata kusihappe taseme tõus, vere uureataseme tõus, vere kreatiniinitaseme tõus
English: No dosage adjustment is necessary in patients with mild hepatic disease.
Estonian: Kergekujulise maksahaigusega patsientidel ei ole annuse kohandamine vajalik.
English: • beta blockers (e.g., labetalol, carvedilol);
Estonian: • beetablokaatorid (nt labetalool, karvedilool).
English: There were no apparent trends toward a greater frequency of haemorrhagic adverse effects in patients taking cilostazol and ASA compared to patients taking placebo and equivalent doses of ASA.
Estonian: Tsilostasooli ja atsetüülsalitsüülhapet võtvatel patsientidel ei esinenud suundumust hemorraagiliste kõrvaltoimete sagenemisele võrreldes platseebot ja samaväärset atsetüülsalitsüülhappe annust võtnud patsientidega.
English: Cytochrome P-450 enzyme inducers
Estonian: Tsütokroom P-450 ensüümi indutseerivad ained
English: No dose adjustment is necessary in patients with a creatinine clearance of > 25 ml/min.
Estonian: Patsientidel, kelle kreatiniini kliirens on > 25 ml/min, ei ole annuse kohandamine vajalik.
English: Paresis, hypoaesthesia
Estonian: Teadmata parees, hüpesteesia
English: Dyspnoea, pneumonia, cough
Estonian: Aeg-ajalt düspnoe, kopsupõletik, köha
English: In rats dosed during pregnancy, foetal weights were decreased.
Estonian: Tiinuse ajal annustamise korral vähenes rottidel loote kehamass.
English: A higher rate of haemorrhage was observed with the concomitant use of clopidogrel, ASA and cilostazol in the CASTLE trial.
Estonian: Uuringus CASTLE täheldati klopidogreeli, atsetüülsalitsüülhappe ja tsilostasooli samaaegsel kasutamisel verejooksude sagenemist.
English: The Cmax and AUC of 4'-transhydroxy cilostazol were 173% and 209% greater in subjects with severe renal impairment.
Estonian: 4'-trans-hüdroksütsilostasooli Cmax ja AUC olid raske neerufunktsiooni kahjustusega uuringus osalejatel 173% ja 209% suuremad.
English: STATEMENT OF ACTIVE SUBSTANCE(S) One tablet contains 50 mg of cilostazol.
Estonian: TOIMEAINE(TE) SISALDUS Üks tablett sisaldab 50 mg tsilostasooli.
English: Cilostazol treatment is contraindicated in patients receiving two or more additional antiplatelet/anticoagulant agents (see section 4.3).
Estonian: Kaht või rohkemat täiendavat trombotsüütide-/hüübimisvastast ravimit kasutavatele patsientidele on tsilostasoolravi vastunäidustatud (vt lõik 4.3).
English: For breast-feeding mothers use of <Cilostazol-containing medicinal product> is NOT RECOMMENDED.
Estonian: Imetavatel emadel EI OLE SOOVITATAV <Tsilostasooli sisaldavat ravimpreparaati> kasutada.
English: Administration of cilostazol with omeprazole (an inhibitor of CYP2C19) increased the AUC of cilostazol by 22%, accompanied by a 68% increase in the AUC of the dehydro metabolite and a decrease of 36% in the AUC of the 4`-trans hydroxy metabolite.
Estonian: Tsilostasooli manustamisel koos omeprasooliga (CYP2C19 inhibiitor) suurenes tsilostasooli AUC 22% võrra, millega kaasnes dehüdrometaboliidi AUC 68% suurenemine ja 4`-transhüdroksümetaboliidi AUC 36% vähenemine.
English: NAME OF THE MARKETING AUTHORISATION HOLDER [See Annex I - To be completed nationally]
Estonian: MÜÜGILOA HOIDJA NIMI [Täidetakse riiklikult] [Vaata I lisa - täidetakse riiklikult]
English: stroke heart attack heart problems which can cause shortness of breath or ankle swelling irregular heart beat (new or worsening)
Estonian: • südamehäired, mis võivad põhjustada hingeldust või pahkluupiirkonna turseid
English: 6.6 Special precautions for disposal <and other handling> No special requirements.
Estonian: 6.6 Erihoiatused ravimpreparaadi hävitamiseks <ja käsitlemiseks>
English: The other ingredients are maize starch, microcrystalline cellulose, carmellose calcium, hypromellose and magnesium stearate.
Estonian: • Teised koostisained on maisitärklis, mikrokristalne tselluloos, karmellooskaltsium,
English: Based on AUC, the overall pharmacological activity of cilostazol increases 35% when co-administered with ketoconazole.
Estonian: AUC põhjal suureneb tsilostasooli üldine farmakoloogiline aktiivsus 35% võrra selle manustamisel koos ketokonasooliga.
English: White, round, flat faced tablets debossed with “OG31” on one side.
Estonian: Valged ümmargused lamedad tabletid, mille ühele küljele on pressitud “OG31”.
English: The elderly
Estonian: Eakad
English: Cilostazol is only recommended for patients whose symptoms have not improved sufficiently after making life-style modifications (such as stopping smoking and increasing exercise) and after other appropriate interventions.
Estonian: Tsilostasooli on soovitatav kasutada ainult patsientidel, kellel muudatused elustiilis (sealhulgas suitsetamisest loobumine ja kehalise aktiivsuse suurendamine) ja muud sobivad sekkumised ei ole vahelduva lonkamise sümptomeid piisavalt parandanud.
English: Administration of cilostazol with diltiazem (a weak inhibitor of CYP3A4) resulted in an increase in the AUC of cilostazol of 44%, accompanied by a 4% increase in AUC of the dehydro metabolite and a 43% increase in the AUC of the 4`-trans-hydroxy metabolite.
Estonian: Tsilostasooli manustamine koos diltiaseemiga (CYP3A4 nõrk inhibiitor) suurendas tsilostasooli AUC-d 44%, millega kaasnes dehüdrometaboliidi AUC suurenemine 4% ja 4`-transhüdroksümetaboliidi AUC suurenemine 43%.
English: One tablet contains 50 mg cilostazol.
Estonian: Üks tablett sisaldab 50 mg tsilostasooli.
English: Eye haemorrhage, epistaxis, gastrointestinal haemorrhage, haemorrhage unspecified, orthostatic hypotension
Estonian: Aeg-ajalt silma veritsemine, ninaverejooks, seedetrakti verejooks, täpsustamata verejooks, ortostaatiline hüpotensioon
English: White, round, flat faced tablets debossed with “OG30” on one side.
Estonian: Valged ümmargused lamedad tabletid, mille ühele küljele on pressitud “OG30”.
English: Co-administration of ketoconazole (an inhibitor of CYP3A4 with cilostazol resulted in a 117% increase in the AUC of cilostazol, accompanied by a 15% decrease in the AUC of the dehydro metabolite and a 87% increase in the AUC of the 4`-trans-hydroxy metabolite.
Estonian: Ketokonasooli (CYP3A4 inhibiitor) ja tsilostasooli koos manustamisel suurenes tsilostasooli AUC 117% võrra, millega kaasnes dehüdrometaboliidi AUC 15% vähenemine ja 4`-transhüdroksümetaboliidi AUC 87% suurenemine.
English: One tablet contains 100 mg of cilostazol.
Estonian: Üks tablett sisaldab 100 mg tsilostasooli.
English: The stomach should be emptied by induced vomiting or gastric lavage, as appropriate.
Estonian: Mao tühjendamiseks võib vajaduse korral oksendamise esile kutsuda ja teha maoloputuse.
English: Myocardial infarction, atrial fibrillation, congestive heart failure, supraventricular tachycardia, ventricular tachycardia, syncope
Estonian: Aeg-ajalt müokardiinfarkt, kodade virvendus, südame paispuudulikkus, supraventrikulaarne tahhükardia, ventrikulaartahhükardia, minestus
English: Administration of cilostazol with erythromycin (an inhibitor of CYP3A4) resulted in an increase in the AUC of cilostazol by 72%, accompanied by a 6% increase in AUC of the dehydro metabolite and a 119% increase in AUC of the 4`-trans-hydroxy metabolite.
Estonian: Tsilostasooli manustamisel koos erütromütsiiniga (CYP3A4 inhibiitor) suurenes tsilostasooli AUC 72%, millega kaasnes dehüdrometaboliidi AUC 6% vähenemine, kuid 4`-trans-hüdroksümetaboliidi AUC 119% suurenemine.
English: Rare side effects (affecting less than 1 in 1,000, but more than 1 in 10,000 people): tendency to bleed for longer than usual increase in the platelets in the blood problems with the kidneys
Estonian: Harvad kõrvaltoimed (esinevad vähem kui 1 patsiendil 1000st, kuid rohkem kui 1 patsiendil 10 000st)
English: Cilostazol did not alter fertility in animal studies.
Estonian: Loomkatsetes tsilostasool viljakust ei mõjutanud.
English: Blood and the lymphatic system disorders
Estonian: Vere ja lümfisüsteemi häired Sage ekhümoos
English: noticeable bleeding easy bruising serious illness with blistering of the skin, mouth, eyes and genitals yellowing of the skin or whites of the eyes caused by liver or blood problems (jaundice)
Estonian: • naha või silmamunade kollaseks värvumine maksa- või verehäirete tõttu (kollatõbi)
English: Palpitation, tachycardia, angina pectoris, arrhythmia, ventricular extrasystoles
Estonian: Sage südamepekslemine, tahhükardia, stenokardia, arütmia, vatsakeste ekstrasüstolid
English: Known hypersensitivity to cilostazol or to any of the excipients Severe renal impairment: creatinine clearance of  25 ml/min Moderate or severe hepatic impairment
Estonian: • raske neerukahjustus: kreatiniini kliirens ≤ 25 ml/min
English: Cilostazol is contraindicated in patients with a creatinine clearance of  25 ml/min.
Estonian: Patsientidele, kelle kreatiniini kliirens on ≤ 25 ml/min, on tsilostasool vastunäidustatud.
English: MARKETING AUTHORISATION HOLDER [See Annex I - To be completed nationally]
Estonian: Müügiloa hoidja ja tootja [Täidetakse riiklikult] [Vaata I lisa - täidetakse riiklikult]
English: NAME OF THE MEDICINAL PRODUCT Cilostazol-containing medicinal products (see Annex I) 50 mg tablets Cilostazol-containing medicinal products (see Annex I) 100 mg tablets [See Annex I - To be completed nationally] Cilostazol
Estonian: RAVIMPREPARAADI NIMETUS Tsilostasooli sisaldav ravimpreparaat (vt I lisa) 50 mg tabletid Tsilostasooli sisaldav ravimpreparaat (vt I lisa) 100 mg tabletid [Vaata I lisa - täidetakse riiklikult] Tsilostasool
English: <Cilostazol-containing medicinal product> 50 mg <Cilostazol-containing medicinal product> 100 mg [To be completed nationally]
Estonian: < Läkemedel som innehåller cilostazol > 100 mg tabletter Ühendkuningriik < Cilostazol-containing medicinal product > 100 mg tablets
English: Based on AUC, overall pharmacological activity of cilostazol increases 19 % when co-administered with diltiazem.
Estonian: Tsilostasooli üldine farmakoloogiline aktiivsus suureneb AUC põhjal 19% selle manustamisel koos diltiaseemiga.
English: Based on AUC, the overall pharmacological activity of cilostazol increases 34% when co-administered with erythromycin.
Estonian: Tsilostasooli üldine farmakoloogiline aktiivsus suureneb AUC põhjal 34% selle manustamisel koos erütromütsiiniga.
English: NAME OF THE MEDICINAL PRODUCT Cilostazol-containing medicinal product (see Annex I) 50 mg tablets Cilostazol-containing medicinal product (see Annex I) 100 mg tablets [See Annex I - To be completed nationally]
Estonian: RAVIMPREPARAADI NIMETUS Tsilostasooli sisaldav ravimpreparaat (vt I lisa) 50 mg tabletid Tsilostasooli sisaldav ravimpreparaat (vt I lisa) 100 mg tabletid [Vaata I lisa - täidetakse riiklikult]
English: Hepatitis, hepatic function abnormal, jaundice
Estonian: Maksa ja sapiteede häired Teadmata hepatiit, maksafunktsiooni häire, kollatõbi
English: BEFORE YOU TAKE <CILOSTAZOL-CONTAINING MEDICINAL PRODUCT>
Estonian: et võtate <Tsilostasooli sisaldavat ravimpreparaati>;
English: Caution is advised when coadministering cilostazol with any drug that inhibits platelet aggregation.
Estonian: Tsilostasooli manustamisel koos ükskõik millise trombotsüütide agregatsiooni pärssiva ravimiga tuleb olla ettevaatlik.
English: What <Cilostazol-containing medicinal product> contains The active substance is cilostazol.
Estonian: Mida <Tsilostasooli sisaldav ravimpreparaat> sisaldab
English: Inhibitors of platelet aggregation
Estonian: Trombotsüütide agregatsiooni pärssivad ained
English: Gastritis
Estonian: Rasedus
English: Cilostazol-containing medicinal products (see Annex I) 50 mg tablets Cilostazol-containing medicinal products (see Annex I) 100 mg tablets Cilostazol [See Annex I - To be completed nationally]
Estonian: Tsilostasooli sisaldav ravimpreparaat (vt I lisa) 50 mg tabletid Tsilostasooli sisaldav ravimpreparaat (vt I lisa) 100 mg tabletid Tsilostasool [Vaata I lisa - täidetakse riiklikult]
English: During treatment with <Cilostazol-containing medicinal product> make sure that
Estonian: Ravi ajal <Tsilostasooli sisaldava ravimpreparaadiga>:
English: The following side effects have been reported for <Cilostazol-containing medicinal product>.
Estonian: <Tsilostasooli sisaldava ravimpreparaadi> kasutamisel on esinenud järgmisi kõrvaltoimeid.
English: HOW TO STORE <CILOSTAZOL-CONTAINING MEDICINAL PRODUCT> Keep <Cilostazol-containing medicinal product> out of the reach and sight of children.
Estonian: Hoidke <Tsilostasooli sisaldavat ravimpreparaati> laste eest varjatud ja kättesaamatus kohas.
English: An increase in the frequency of palpitation and peripheral oedema was observed when cilostazol was combined with other vasodilators that cause reflex tachycardia e.g. dihydropyridine calcium channel blockers.
Estonian: Tsilostasooli kasutamisel koos teiste vasodilataatoritega, mis põhjustavad reflekstahhükardiat, nt dihüdropüridiini tüüpi kaltsiumikanali blokaatoritega, suurenes südamepekslemise ja perifeerse turse esinemissagedus.
English: The excretion of cilostazol in human milk is unknown.
Estonian: Loomkatsetes eritus tsilostasool piima.
English: Based on these data, the recommended dose of cilostazol is 50 mg bid in the presence of ketoconazole and similar agents (e.g., itraconazole).
Estonian: Nende andmete põhjal on ketokonasooli ja muude sarnaste ainete (nt itrakonasooli) samaaegsel kasutamisel tsilostasooli soovitatav annus 50 mg kaks korda päevas.
English: Do not take <Cilostazol-containing medicinal product> if you are allergic (hypersensitive) to cilostazol or any of the other ingredients of <Cilostazolcontaining medicinal product>.
Estonian: • kui olete tsilostasooli või selle ravimi mis tahes koostisosa suhtes allergiline;
English: Hyperglycaemia, Diabetes mellitus
Estonian: Aeg-ajalt hüperglükeemia, suhkurtõbi
English: Hepatic impairment
Estonian: Väga sage peavalu
English: Take special care with <Cilostazol-containing medicinal product> Before taking <Cilostazol-containing medicinal product> make sure your doctor knows: if you have a severe heart problem or any problems with your heart beat.
Estonian: Hoiatused ja ettevaatusabinõud seoses <Tsilostasooli sisaldava ravimpreparaadiga> Enne <Tsilostasooli sisaldava ravimpreparaadi> võtmist pidage nõu oma arstiga:
English: Chest pain, asthenia
Estonian: Teadmata palavik, valu
English: Pyrexia, pain
Estonian: Sage lööve, kihelus
English: Renal impairment
Estonian: Aeg-ajalt aneemia
English: - problems with your eyes if you have diabetes.
Estonian: − silmade häired seoses suhkurtõvega;
English: Based on these data, the recommended dose of cilostazol is 50 mg bid in the presence of erythromycin and similar agents (e.g., clarithromycin).
Estonian: Nende andmete põhjal on erütromütsiini ja muude sarnaste ainete (nt klaritromütsiini) samaaegsel kasutamisel tsilostasooli soovitatav annus 50 mg kaks korda päevas.
English: You should check with your doctor or pharmacist if you are not sure.
Estonian: pidage nõu oma arsti või apteekriga].
English: • acetylsalicylic acid
Estonian: • ketokonasool (seeninfektsioonide raviks)
English: Pregnancy
Estonian: Lapsed
English: This summary was last updated in March 2016.
Estonian: Kokkuvõtte viimane uuendus: 03-2016.
English: The full EPAR for Profender can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Profenderi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The European Commission granted a marketing authorisation valid throughout the EU for Profender on 27 July 2005.
Estonian: Euroopa Komisjon andis Profenderi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 27. juulil
English: Profender should not be allowed to enter surface water, as it may be harmful for aquatic organisms.
Estonian: Profender ei tohi sattuda pinnavette, sest see võib olla veeorganismidele kahjulik.
English: No side effects have been reported in dogs.
Estonian: Koertel ei ole kõrvalnähtudest teatatud.
English: These signs disappear without further treatment.
Estonian: Need nähud kaovad ilma ravita.
English: Profender should not be used in young animals (cats under 8 weeks of age or weighing less than 0.5 kg, or puppies under 12 weeks of age or weighing less than 1 kg).
Estonian: Profenderit ei tohi kasutada noorloomadel (alla 8-nädalastel või alla 0,5 kg kaaluvatel kassipoegadel ja alla 12-nädalastel või alla 1 kg kaaluvatel kutsikatel).
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Profender's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Veterinaarravimite komitee järeldas, et Profenderi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Profender emodepside / praziquantel
Estonian: Profender emodepsiid/prasikvanteel
English: The person giving the dose should not smoke, eat or drink, and should wash their hands thoroughly after use.
Estonian: Ravimi manustamise ajal ei tohi suitsetada, süüa ega juua ning pärast ravimi kasutamist peab korralikult käsi pesema.
English: Profender is an antiparasitic medicine that contains two active substances, emodepside and praziquantel.
Estonian: Profender on parasiidivastane ravim, mis sisaldab kaht toimeainet: emodepsiidi ja prasikvanteeli.
English: The effectiveness of each of the products against the specified roundworms and tapeworms was investigated in both laboratory studies and in large field studies (one for the spot-on for cats and another for the tablets for dogs) carried out at several different places across Europe.
Estonian: Iga ravimi tõhusust konkreetsete ümar- ja paelusside vastu uuriti nii laborikatsetes kui ka ulatuslikes väliuuringutes (üks kasside täpilahuse uuring ja üks koerte tablettide uuring), mis korraldati Euroopa eri kohtades.
English: This is a summary of the European public assessment report (EPAR) for Profender.
Estonian: See on ravimi Profender Euroopa avaliku hindamisaruande kokkuvõte.
English: The two active substances in Profender interact with different parts of the parasites systems.
Estonian: Profenderi kaks toimeainet mõjutavad parasiitide süsteemide eri osi.
English: Other information about Profender:
Estonian: Muu teave Profenderi kohta
English: What is Profender and what is it used for?
Estonian: Mis on Profender ja milleks seda kasutatakse?
English: The solvent in Profender spot-on solution may stain certain materials including leather, fabrics, plastics and finished surfaces, so contact between the product and such surfaces should be avoided.
Estonian: Profenderis olev lahusti võib määrida teatud materjale, sealhulgas nahka, riiet, plasti ja viimistletud pindasid, mistõttu tuleb vältida toote sattumist nendele pindadele.
English: The correct number of tablets or half tablets to use is calculated based on the dog's weight.
Estonian: Tablettide või poolitatud tablettide sobiv arv määratakse koera kehakaalu alusel.
English: In cats, in very rare cases, the cat might salivate or vomit after treatment.
Estonian: Kassidel võib väga harvadel juhtudel esineda pärast ravi süljevool või oksendamine.
English: Why is Profender approved?
Estonian: Miks Profender heaks kiideti?
English: If accidental exposure occurs, the eyes should be rinsed with water or the skin washed with soap and water.
Estonian: Juhuslikul kokkupuutel loputage silmi veega või peske nahka seebi ja veega.
English: Profender tablets are available in three different strengths to cover a range of dog weights (small, medium or large dogs).
Estonian: Prodenderi tabletid on kolme tugevusega, mis on ette nähtud eri kehakaaluga koertele (väikesed, keskmise suurusega ja suured koerad).